Investment case
Fortrea Holdings Inc.
FTRE · 5 developments mapped · last assessed 2026-09-03
Market Ontology has mapped 5 macro, policy, and market developments to Fortrea Holdings Inc. since 2026-09-03. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for FTRE yet, so no modelled value is shown. The FTRE valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run FTRE on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Fortrea to Acquire Worldwide Clinical Trials Early Phase Division for $45 Million
Direct expansion of service capabilities and geographic footprint in early-phase clinical trials, potentially leading to increased revenue and operational synergies.
· Moves revenue growth rate, ebitda margin, capital expenditures
- Open question
Fortrea to Acquire Worldwide Clinical Early Phase Unit for $45M
Strategic acquisition to expand early-phase clinical research capabilities and market share. Integration risks and potential for synergy realization.
· Moves growth rate of early phase clinical research segment, synergy realization rate, integration costs and timeline
What changed, by assumption
- 2026-09-03Fortrea to Acquire Worldwide Clinical Early Phase Unit for $45M
- 2026-09-03Fortrea to Acquire Worldwide Clinical Trials Early Phase Division for $45 Million
- 2026-09-03Fortrea to Acquire Worldwide Clinical Trials Early Phase Unit for $45M
- 2026-09-03Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45 Million
- 2026-09-03Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45M
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-03 | Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45M | mixed | 3-12m | 0.60 |
| 2026-09-03 | Fortrea to Acquire Worldwide Clinical Early Phase Unit for $45M | mixed | 1-3m | 0.70 |
| 2026-09-03 | Fortrea to Acquire Worldwide Clinical Trials Early Phase Unit for $45M | Bullish | 1-3m | 0.60 |
| 2026-09-03 | Fortrea to Acquire Worldwide Clinical Trials Early Phase Division for $45 Million | Bullish | 3-12m | 0.70 |
| 2026-09-03 | Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45 Million | Bullish | 1-3m | 0.70 |